17321-97-0

Usage

Uses

Used in Pharmaceutical Industry:
2-Amino-4-methylpyrimidine-5-carbonitrile is used as a key intermediate for the synthesis of various drugs, contributing to the development of new therapeutic agents.
Used in Organic Synthesis:
2-Amino-4-methylpyrimidine-5-carbonitrile is utilized as a versatile building block in organic synthesis, enabling the creation of a wide range of different compounds with diverse applications.
Used in Drug Development:
2-Amino-4-methylpyrimidine-5-carbonitrile is investigated for its potential in drug development, particularly for its antitumor and antiviral properties, which could lead to the discovery of novel treatments for various diseases.
Used in Scientific Research:
Due to its importance in both drug development and organic chemistry, 2-Amino-4-methylpyrimidine-5-carbonitrile remains a subject of interest in the scientific community, with ongoing research aimed at uncovering its full potential and expanding its applications.

InChI:InChI=1/C6H6N4/c1-4-5(2-7)3-9-6(8)10-4/h3H,1H3,(H2,8,9,10)

Upstream product

• 17321-93-6 5-bromo-4-methylpyrimidine-2-ylamine 
• 544-92-3 copper(I) cyanide 
• 858135-88-3 (E)-2-((dimethylamino)methylene)-3-oxobutanenitrile 
• 593-85-1 guanidine carbonate 

Downstream Products

• 19594-45-7 5-aminomethyl-4-methyl-pyrimidin-2-ylamine 

Relevant academic research and scientific papers

SUBSTITUTED NITROGEN CONTAINING COMPOUNDS

Disclosed are compounds of Formula (I): or a salt thereof, Formula (II) wherein R1 is: or; each W is independently NR1b or O; Z is a bond or CHR1d; and R1, R2, Rd, R3a, R3b, L1, B, V, Y, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of ROMK, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating cardiovascular diseases.

SUBSTITUTED BICYCLE HETEROCYCLIC DERIVATIVES USEFUL AS ROMK CHANNEL INHIBITORS

Disclosed are compounds of Formula (I) or a salt thereof, wherein R1 is (II) or (III); each W is independently NR1b or O; Z is a bond or CHR1d; and R1, R2, Rd, R3, L1, L2, R1a, R1b, R1c, and n are define herein. Also disclosed are methods of using such compounds as inhibitors of ROMK, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating cardiovascular diseases.

Non-covalent thrombin inhibitors featuring P3-heterocycles with P1-monocyclic arginine surrogates

Investigations on P2-P3-heterocyclic dipeptide surrogates directed towards identification of an orally bioavailable thrombin inhibitor led us to pursue novel classes of achiral, non-covalent P1-arginine derivatives. The design, synthesis, and biological activity of inhibitors NC1-NC30 that feature three classes of monocyclic P1-arginine surrogates will be disclosed: (1) (hetero)aromatic amidines, amines and hydroxyamidines, (2) 2-aminopyrazines, and (3) 2-aminopyrimidines and 2-aminotetrahydropyrimidines.